.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Drug patents and clinical trials in dozens of countries
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Fish and Richardson
Citi
Chinese Patent Office
Novartis
UBS
Merck
Boehringer Ingelheim
Argus Health
Cantor Fitzgerald

Generated: June 23, 2017

DrugPatentWatch Database Preview

Oxybutynin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for oxybutynin and what is the scope of oxybutynin freedom to operate?

Oxybutynin
is the generic ingredient in eight branded drugs marketed by Allergan Sales Llc, Barr Labs Div Teva, Mylan, Osmotica Pharm Us, Amneal Pharms, Ortho Mcneil Janssen, Silarx, Unique Pharm Labs, Usl Pharma, Pharm Assoc, Accord Hlthcare, Mikart, Mylan Pharms Inc, Impax Pharms, Teva Pharms Usa, Wockhardt, Janssen Pharms, Vintage Pharms, Watson Labs, Quantum Pharmics, and Apotex Inc, and is included in twenty-seven NDAs. There are twelve patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Oxybutynin has one hundred and eight patent family members in twenty-two countries.

There are sixteen drug master file entries for oxybutynin. Two suppliers are listed for this compound.

Summary for Generic Name: oxybutynin

Tradenames:8
Patents:12
Applicants:21
NDAs:27
Drug Master File Entries: see list16
Suppliers / Packagers: see list2
Bulk Api Vendors: see list51
Clinical Trials: see list71
Patent Applications: see list4,954
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:oxybutynin at DailyMed

Pharmacology for Ingredient: oxybutynin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Quantum Pharmics
OXYBUTYNIN CHLORIDE
oxybutynin chloride
TABLET;ORAL072296-001Dec 8, 1988DISCNNoNo► Subscribe► Subscribe
Janssen Pharms
DITROPAN XL
oxybutynin chloride
TABLET, EXTENDED RELEASE;ORAL020897-001Dec 16, 1998ABRXYesNo► Subscribe► Subscribe
Ortho Mcneil Janssen
DITROPAN
oxybutynin chloride
SYRUP;ORAL018211-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
Vintage Pharms
OXYBUTYNIN CHLORIDE
oxybutynin chloride
SYRUP;ORAL076682-001Dec 28, 2004AARXNoNo► Subscribe► Subscribe
Janssen Pharms
DITROPAN
oxybutynin chloride
TABLET;ORAL017577-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: oxybutynin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 20035,834,010► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 20135,601,839► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 20035,164,190► Subscribe
Allergan Sales Llc
OXYTROL
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL021351-002Feb 26, 20035,601,839► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 20135,834,010► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: oxybutynin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,214,381Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
7,404,965Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
7,387,788Pharmaceutical compositions of nicotine and methods of use thereof► Subscribe
8,652,491Transdermal compositions for anticholinergic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: oxybutynin

Country Document Number Estimated Expiration
South Africa200602046► Subscribe
South Korea20110043725► Subscribe
New Zealand546106► Subscribe
South Korea20130026510► Subscribe
European Patent Office1280486► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
McKesson
Argus Health
Cantor Fitzgerald
Dow
Farmers Insurance
US Army
Boehringer Ingelheim
Daiichi Sankyo
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot